English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Zendy Plus

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Zendy Tools

Zendy Open

Rationale, aims and objectives  Clinical trial data suggest that patients who have received bisphosphonates continue to benefit from them after discontinuation. However, data from real‐world clinical practice are inconclusive. We assessed the impact of persistence and discontinuation on health resource utilization ( HRU ) and fracture rate in women who were prescribed oral bisphosphonates.    Method  The study used data from the  UK C linical  P ractice  R esearch  D atalink. Women aged 50 years or older with a first prescription of oral bisphosphonate therapy between  J anuary 2000 and  D ecember 2007 were included. Multivariate modelling compared rate ratios for fracture and  HRU  between patients who had discontinued medication (shorter persistence group) and patients who took their medication for longer (longer persistence group). The interactions of elapsed time (measured as 6‐month intervals) with  HRU  and with fracture rate for all patients within paired groups were also assessed.    Results  Overall, 36 320 patients were included. Pairwise comparisons showed that  HRU  and fracture rates were lower in longer persistence groups than in shorter persistence groups. Analysis by 6‐month interval showed that, across all patients in persistence group pairs,  HRU  significantly increased for each additional 6 months elapsed; trends towards increased risk of fracture were also seen.    Conclusion  In contrast to results from clinical trials, in this patient population the protective effect of oral bisphosphonates after discontinuation was not sufficient to reduce  HRU  and fracture rates to the levels that would be seen if patients had continued on therapy. Reducing the rate of treatment discontinuation may decrease the burden that osteoporosis places on both patients and health care systems.

journal of evaluation in clinical practice

The impact of persistence with bisphosphonates on health resource utilization and fracture risk in the  UK : a study of patient records from the  UK C linical  P ractice  R esearch  D atalink